A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors

This study is testing a drug called STRO-002 in adults in China who have advanced ovarian cancer or other solid tumors that have returned or worsened after prior treatment. STRO-002 is an antibody-drug conjugate — a targeted therapy that delivers a toxic payload directly to cancer cells. **You may be eligible if...** - You have advanced solid tumor cancer (ovarian, fallopian tube, primary peritoneal, or endometrial cancer for dose expansion cohorts) - You have at least one measurable tumor on scans - You have received prior standard treatment and your cancer has returned or progressed - Your organs (heart, kidneys, liver, bone marrow) are functioning adequately - Your life expectancy is more than 3 months **You may NOT be eligible if...** - You have significant heart rhythm abnormalities (prolonged QT interval) - You have not recovered from side effects of prior cancer treatments - You have had no prior standard treatment when it is available - You do not have measurable disease on scans Talk to your doctor to see if this trial is right for you.